搜尋
Harrow Inc
HROW添加自選
41.500USD
-1.180-2.76%
收盤 06/25, 16:00（美東）報價延遲15分鐘
1.55B總市值
虧損本益比TTM
關鍵數據
42.750今開
43.115最高
678.11K成交量
虧損本益比TTM
16.65本益比動
--股利TTM
1.82%換手率
42.680昨收
41.250最低
22.63M成交額
虧損本益比靜
53.88市淨率
0.00%股息率 TTM
-3.82%ROA
54.85052週最高
0.65量比
-17.48M淨利潤
37.27M總股本
-0.3849每股盈餘TTM
0.29Beta
-35.14%ROE
25.68052週最低
4.37%振幅
61.18%毛利率
1.55B總市值
6.88回報/風險
3.49%風險率
TradingKey Harrow Inc股票評分
單位: USD 更新時間: 2026-06-24操作建議
Harrow Inc當前公司基本面數據相對穩定，增長潛力很大。當前估值合理，在藥品行業排名47/157位。機構持股佔比非常高，近一月多位分析師給出公司評級為買入。最高目標價為65.57。中期看，股價處於上升通道。近一個月，市場表現很強，技術面和基本面綜合得分較高，很強的走勢得到基本面和技術面的印證。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Harrow Inc評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
公司輿情
過去24小時
熱度
過冷
過熱
中性
Harrow Inc亮點
亮點風險
Harrow, Inc. is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the North American market. The Company offers a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
業績高增長
公司營業收入穩步增長，連續3年增長109.15%
估值低估
公司最新PE估值-110.89，處於3年歷史低位
機構加倉
最新機構持股24.67M股，環比增加1.39%
私人資本持倉
明星投資者私人資本持倉，最新持倉1.60M股
分析師目標
基於
8
分析師
買入
評級
65.571
目標均價
+53.28%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
Harrow Inc新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Harrow Inc簡介
Harrow, Inc. is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the North American market. The Company offers a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
公司代碼HROW
公司Harrow Inc
CEOMullery (Frank)
網址https://www.harrow.com/
相關品種
+1.16%
+1.66%
+1.48%
+3.67%
+4.05%
+1.27%
+0.40%
+0.44%
-1.05%
-1.48%
+1.05%
+0.75%
+1.55%
+1.14%
-0.20%
0.00%
-0.53%
+0.73%
+4.24%
-0.54%熱門品種
52039.900
+15.200 (+0.03%)
29361.700
-93.300 (-0.32%)
7359.500
-7.300 (-0.10%)
15654.000
-97.000 (-0.62%)
70380.000
-752.000 (-1.06%)
6257.800
-8.000 (-0.13%)
71.598
+0.254 (+0.36%)
275.150
-17.930 (-6.12%)
195.740
-3.260 (-1.64%)
4015.880
-10.270 (-0.26%)
常見問題
Harrow Inc(HROW)的當前股價是多少？
Harrow Inc(HROW)的當前股價是 41.50。
Harrow Inc 的股票代碼是什麼？
Harrow Inc的股票代碼是HROW。
Harrow Inc股票的52週最高點是多少？
Harrow Inc股票的52週最高點是54.85。
Harrow Inc股票的52週最低點是多少？
Harrow Inc股票的52週最低點是25.68。
Harrow Inc的市值是多少？
Harrow Inc的市值是1.55B。
現在Harrow Inc(HROW)的股票是買入、持有還是賣出？
根據分析師評級，Harrow Inc(HROW)的總體評級為買入，目標價格為65.57。
Harrow Inc(HROW)股票的每股收益（EPS TTM）是多少
Harrow Inc(HROW)股票的每股收益（EPS TTM）是-0.14。
